Last updated on March 2018

Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients


Brief description of study

This is a clinical trial comparing the immunosuppressive treatment determined according to two biomarkers, donor-specific IFN- ELISPOT and Mismatch of HLA between donor and recipient, in patients undergoing low immunological risk live donor kidney transplantation

Detailed Study Description

This is a national multicenter clinical trial, controlled, randomized, stratified, parallel groups, and without masking.

This is a prospective intervention study in which two strategies for determining immunosuppressive treatment in kidney transplant patients from a live donor with low immunological risk are compared according to solid phase antibody detection techniques (cPRA 0% and isolated negative antigen) and crossmatch by negative cytotoxicity. Patients are randomized in a 1: 1 ratio to receive one of two immunosuppressive treatment strategies.

Clinical Study Identifier: NCT03465397

Contact Investigators or Research Sites near you

Start Over

ORIOL BESTARD, DR

Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Spain
  Connect »

LAURA CAÑAS

Hospital Universitari Germans Trias I Pujol
Badalona, Spain
  Connect »

CARME FACUNDO, DR

Fundaci Puigvert
Barcelona, Spain
  Connect »

FRITZ DIEKMANN, DR

Hospital Clinic
Barcelona, Spain
  Connect »

MARTA CRESPO, DR

Hospital Del Mar
Barcelona, Spain
  Connect »

FRANCESC MORESO, DR

Hospital Universitari Vall D'Hebr n
Barcelona, Spain
  Connect »